1
|
Baldo A, Di Domizio J, Yatim A, Vandenberghe-Dürr S, Jenelten R, Fries A, Grizzetti L, Kuonen F, Paul C, Modlin RL, Conrad C, Gilliet M. Human neutrophils drive skin autoinflammation by releasing interleukin (IL)-26. J Exp Med 2024; 221:e20231464. [PMID: 38448036 PMCID: PMC10917069 DOI: 10.1084/jem.20231464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 01/04/2024] [Accepted: 02/09/2024] [Indexed: 03/08/2024] Open
Abstract
Autoinflammation is a sterile inflammatory process resulting from increased neutrophil infiltration and overexpression of IL-1 cytokines. The factors that trigger these events are, however, poorly understood. By investigating pustular forms of psoriasis, we show that human neutrophils constitutively express IL-26 and abundantly release it from granular stores upon activation. In pustular psoriasis, neutrophil-derived IL-26 drives the pathogenic autoinflammation process by inducing the expression of IL-1 cytokines and chemokines that further recruit neutrophils. This occurs via activation of IL-26R in keratinocytes and via the formation of complexes between IL-26 and microbiota DNA, which trigger TLR9 activation of neutrophils. Thus our findings identify neutrophils as an important source of IL-26 and point to IL-26 as the key link between neutrophils and a self-sustaining autoinflammation loop in pustular psoriasis.
Collapse
Affiliation(s)
- Alessia Baldo
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Jeremy Di Domizio
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Ahmad Yatim
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Sophie Vandenberghe-Dürr
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Raphael Jenelten
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Anissa Fries
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Lorenzo Grizzetti
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| | - François Kuonen
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Carle Paul
- Department of Dermatology and Venereology, Centre Hospitalier Universitaire, Toulouse, France
| | - Robert L. Modlin
- Division of Dermatology, University of California, Los Angeles, Los Angeles, CA, USA
| | - Curdin Conrad
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Michel Gilliet
- Department of Dermatology and Venereology, University Hospital of Lausanne, Lausanne, Switzerland
| |
Collapse
|
2
|
Chang YT, Prompsy P, Kimeswenger S, Tsai YC, Ignatova D, Pavlova O, Iselin C, French LE, Levesque MP, Kuonen F, Bobrowicz M, Brunner PM, Pascolo S, Hoetzenecker W, Guenova E. MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides. Nat Commun 2024; 15:752. [PMID: 38272918 PMCID: PMC10810852 DOI: 10.1038/s41467-024-45083-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 01/15/2024] [Indexed: 01/27/2024] Open
Abstract
Cancer-associated immune dysfunction is a major challenge for effective therapies. The emergence of antibodies targeting tumor cell-surface antigens led to advancements in the treatment of hematopoietic malignancies, particularly blood cancers. Yet their impact is constrained against tumors of hematopoietic origin manifesting in the skin. In this study, we employ a clonality-supervised deep learning methodology to dissect key pathological features implicated in mycosis fungoides, the most common cutaneous T-cell lymphoma. Our investigations unveil the prominence of the IL-32β-major histocompatibility complex (MHC)-I axis as a critical determinant in tumor T-cell immune evasion within the skin microenvironment. In patients' skin, we find MHC-I to detrimentally impact the functionality of natural killer (NK) cells, diminishing antibody-dependent cellular cytotoxicity and promoting resistance of tumor skin T-cells to cell-surface targeting therapies. Through murine experiments in female mice, we demonstrate that disruption of the MHC-I interaction with NK cell inhibitory Ly49 receptors restores NK cell anti-tumor activity and targeted T-cell lymphoma elimination in vivo. These findings underscore the significance of attenuating the MHC-I-dependent immunosuppressive networks within skin tumors. Overall, our study introduces a strategy to reinvigorate NK cell-mediated anti-tumor responses to overcome treatment resistance to existing cell-surface targeted therapies for skin lymphoma.
Collapse
Affiliation(s)
- Yun-Tsan Chang
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Pacôme Prompsy
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Susanne Kimeswenger
- Department of Dermatology and Venerology, Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Yi-Chien Tsai
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Desislava Ignatova
- Department of Dermatology, University Hospital of Zurich and Faculty of Medicine, University of Zurich, Zurich, Switzerland
| | - Olesya Pavlova
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Christoph Iselin
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Lars E French
- Department of Dermatology and Allergology, Ludwig-Maximilians-University of Munich, Munich, Germany
- Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Mitchell P Levesque
- Department of Dermatology, University Hospital of Zurich and Faculty of Medicine, University of Zurich, Zurich, Switzerland
| | - François Kuonen
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | | | - Patrick M Brunner
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA
| | - Steve Pascolo
- Department of Dermatology, University Hospital of Zurich and Faculty of Medicine, University of Zurich, Zurich, Switzerland
| | - Wolfram Hoetzenecker
- Department of Dermatology and Venerology, Medical Faculty, Johannes Kepler University, Linz, Austria.
| | - Emmanuella Guenova
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
- Department of Dermatology, University Hospital of Zurich and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
- Department of Dermatology, Hospital 12 de Octubre, Medical School, University Complutense, Madrid, Spain.
| |
Collapse
|
3
|
Tonellotto L, Seremet T, Vernez M, Guenova E, Kuonen F. Fast, bedside diagnosis of toxic epidermal necrolysis using ex vivo confocal laser scanning microscopy: A retrospective study. J Eur Acad Dermatol Venereol 2024; 38:182-185. [PMID: 37593888 DOI: 10.1111/jdv.19424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 07/17/2023] [Indexed: 08/19/2023]
Abstract
BACKGROUND Toxic epidermal necrolysis (TEN) is a severe life-threatening drug eruption with rapid evolution. A fast histologic differentiation between TEN and clinically similarly looking staphylococcal scalded skin syndrome is of vital importance for relevant treatment decision. The recently developed ex vivo confocal laser scanning microscopy (CLSM) offers innovative and extremely fast histological visualization of fresh tissue specimens. OBJECTIVE To assess the diagnostic efficacy of ex vivo CLSM in comparison with standard histopathology for TEN. METHODS We performed side-by-side comparison of TEN specimens analysed with ex vivo CLSM and haematoxylin and eosin staining. Analysis focused on typical histopathological features of TEN, including epidermal cleavage in the basal layer and confluent epidermal necrosis. We retrospectively assessed the diagnostic performance of ex vivo CLSM for TEN in clinically confirmed cases. RESULTS We report substantial agreement between ex vivo CLSM and classical histology for the detection of subepidermal cleavage and confluent epidermal necrosis. When considering full-thickness epidermal loss, epidermal cleavage in the basal layer showed the highest diagnostic performance, reaching 87.5% sensitivity and 100% specificity. CONCLUSION Based on our data, ex vivo CSLM appears as a rapid, resource-optimizing, and reliable approach for morphological TEN emergency screening on fresh skin samples.
Collapse
Affiliation(s)
- L Tonellotto
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - T Seremet
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - M Vernez
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - E Guenova
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Department of Dermatology, Hospital 12 de octubre, Medical school, University Complutense, Madrid, Spain
| | - F Kuonen
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
4
|
Pich-Bavastro C, Yerly L, Di Domizio J, Tissot-Renaud S, Gilliet M, Kuonen F. Activin A-Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer. Clin Cancer Res 2023; 29:3498-3513. [PMID: 37327314 PMCID: PMC10472111 DOI: 10.1158/1078-0432.ccr-23-0219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Revised: 05/05/2023] [Accepted: 06/14/2023] [Indexed: 06/18/2023]
Abstract
PURPOSE Cemiplimab is approved for the treatment of locally advanced basal cell carcinomas (BCC), although with mitigated results. We sought to interrogate the cellular and molecular transcriptional reprogramming underlying BCC resistance to immunotherapy. EXPERIMENTAL DESIGN Here, we combined spatial and single-cell transcriptomics to deconvolute the spatial heterogeneity of the tumor microenvironment in regard with response to immunotherapy, in a cohort of both naïve and resistant BCCs. RESULTS We identified subsets of intermingled cancer-associated fibroblasts (CAF) and macrophages contributing the most to CD8 T-cell exclusion and immunosuppression. Within this spatially resolved peritumoral immunosuppressive niche, CAFs and adjacent macrophages were found to display Activin A-mediated transcriptional reprogramming towards extracellular matrix remodeling, suggesting active participation to CD8 T-cell exclusion. In independent datasets of human skin cancers, Activin A-conditioned CAFs and macrophages were associated with resistance to immune checkpoint inhibitors (ICI). CONCLUSIONS Altogether, our data identify the cellular and molecular plasticity of tumor microenvironment (TME) and the pivotal role of Activin A in polarizing the TME towards immune suppression and ICI resistance.
Collapse
Affiliation(s)
- Christine Pich-Bavastro
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Laura Yerly
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Jeremy Di Domizio
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Stéphanie Tissot-Renaud
- Department of Oncology, Immune Landscape Laboratory, Center of Experimental Therapeutics, Lausanne University Hospital, Lausanne, Switzerland
- Ludwig Institute for Cancer Research Lausanne, Lausanne University Hospital and University of Lausanne, Switzerland
| | - Michel Gilliet
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - François Kuonen
- Department of Dermatology and Venereology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
5
|
Fries A, Saidoune F, Kuonen F, Dupanloup I, Fournier N, Guerra de Souza AC, Haniffa M, Ma F, Gudjonsson JE, Roesner L, Li Y, Werfel T, Conrad C, Gottardo R, Modlin RL, Di Domizio J, Gilliet M. Differentiation of IL-26 + T H17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis. Nat Commun 2023; 14:3878. [PMID: 37391412 PMCID: PMC10313793 DOI: 10.1038/s41467-023-39484-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 06/15/2023] [Indexed: 07/02/2023] Open
Abstract
Interleukin (IL)-26 is a TH17 cytokine with known antimicrobial and pro-inflammatory functions. However, the precise role of IL-26 in the context of pathogenic TH17 responses is unknown. Here we identify a population of blood TH17 intermediates that produce high levels of IL-26 and differentiate into IL-17A-producing TH17 cells upon TGF-β1 exposure. By combining single cell RNA sequencing, TCR sequencing and spatial transcriptomics we show that this process occurs in psoriatic skin. In fact, IL-26+ TH17 intermediates infiltrating psoriatic skin induce TGF-β1 expression in basal keratinocytes and thereby promote their own differentiation into IL-17A-producing cells. Thus, our study identifies IL-26-producing cells as an early differentiation stage of TH17 cells that infiltrates psoriatic skin and controls its own maturation into IL17A-producing TH17 cells, via epithelial crosstalk involving paracrine production of TGF-β1.
Collapse
Affiliation(s)
- Anissa Fries
- Department of Dermatology, CHUV University Hospital and University of Lausanne (UNIL), Lausanne, Switzerland
| | - Fanny Saidoune
- Department of Dermatology, CHUV University Hospital and University of Lausanne (UNIL), Lausanne, Switzerland
| | - François Kuonen
- Department of Dermatology, CHUV University Hospital and University of Lausanne (UNIL), Lausanne, Switzerland
| | - Isabelle Dupanloup
- Translational Data Science Facility, Agora Cancer Research Center, Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Nadine Fournier
- Translational Data Science Facility, Agora Cancer Research Center, Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Ana Cristina Guerra de Souza
- Translational Data Science Facility, Agora Cancer Research Center, Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Muzlifah Haniffa
- Department of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE2 4LP, UK
| | - Feiyang Ma
- Department of Dermatology, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Johann E Gudjonsson
- Department of Dermatology, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Lennart Roesner
- Department of Dermatology, Hannover Medical School, Hannover, Germany
- Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany
| | - Yang Li
- Department of Computational Biology for Individualised Medicine, Centre for Individualised Infection Medicine (CiiM), Helmholtz Centre for Infection Research (HZI), Hannover Medical School (MHH), Hannover, Germany
| | - Thomas Werfel
- Department of Dermatology, Hannover Medical School, Hannover, Germany
- Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany
| | - Curdin Conrad
- Department of Dermatology, CHUV University Hospital and University of Lausanne (UNIL), Lausanne, Switzerland
| | - Raphael Gottardo
- Biomedical Data Sciences Center, CHUV, UNIL, and SIB, Lausanne, Switzerland
| | - Robert L Modlin
- Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA, 90095, USA
| | - Jeremy Di Domizio
- Department of Dermatology, CHUV University Hospital and University of Lausanne (UNIL), Lausanne, Switzerland.
| | - Michel Gilliet
- Department of Dermatology, CHUV University Hospital and University of Lausanne (UNIL), Lausanne, Switzerland.
| |
Collapse
|
6
|
Yerly L, Bavastro CP, Di Domizio J, Wyss T, Tissot S, Cangkrama M, Gilliet M, Werner S, Kuonen F. 432 Integrated multi-omics reveals cellular and molecular interactions governing the invasive niche of basal cell carcinoma. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
7
|
Fries A, Saidoune F, Kuonen F, Conrad C, Dupanloup I, Guerra de Souza A, Fournier N, Gottardo R, Di Domizio J, Gilliet M. 003 Interleukin (IL)-26 drives pathogenic IL-17A responses through a TH17-keratinocyte crosstalk. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
8
|
Lorusso G, Wyss CB, Kuonen F, Vannini N, Billottet C, Duffey N, Pineau R, Lan Q, Wirapati P, Barras D, Tancredi A, Lyck R, Lehr HA, Engelhardt B, Delorenzi M, Bikfalvi A, Rüegg C. Connexins orchestrate progression of breast cancer metastasis to the brain by promoting FAK activation. Sci Transl Med 2022; 14:eaax8933. [PMID: 36070364 DOI: 10.1126/scitranslmed.aax8933] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Brain metastasis is a complication of increasing incidence in patients with breast cancer at advanced disease stage. It is a severe condition characterized by a rapid decline in quality of life and poor prognosis. There is a critical clinical need to develop effective therapies to prevent and treat brain metastases. Here, we describe a unique and robust spontaneous preclinical model of breast cancer metastasis to the brain (4T1-BM2) in mice that has been instrumental in uncovering molecular mechanisms guiding metastatic dissemination and colonization of the brain. Key experimental findings were validated in the additional murine D2A1-BM2 model and in human MDA231-BrM2 model. Gene expression analyses and functional studies, coupled with clinical transcriptomic and histopathological investigations, identified connexins (Cxs) and focal adhesion kinase (FAK) as master molecules orchestrating breast cancer colonization of the brain. Cx31 promoted homotypic tumor cell adhesion, heterotypic tumor-astrocyte interaction, and FAK phosphorylation. FAK signaling prompted NF-κB activation inducing Lamc2 expression and laminin 332 (laminin 5) deposition, α6 integrin-mediated adhesion, and sustained survival and growth within brain parenchyma. In the MDA231-BrM2 model, the human homologous molecules CX43, LAMA4, and α3 integrin were involved. Systemic treatment with FAK inhibitors reduced brain metastasis progression. In conclusion, we report a spontaneous model of breast cancer metastasis to the brain and identified Cx-mediated FAK-NF-κB signaling as a mechanism promoting cell-autonomous and microenvironmentally controlled cell survival for brain colonization. Considering the limited therapeutic options for brain metastatic disease in cancer patients, we propose FAK as a therapeutic candidate to further pursue in the clinic.
Collapse
Affiliation(s)
- Girieca Lorusso
- Experimental and Translational Oncology, Pathology Unit, Department of Oncology Microbiology and Immunology (OMI), Faculty of Science and Medicine, University of Fribourg, Fribourg 1700, Switzerland.,Division of Experimental Oncology, Multidisciplinary Oncology Center (CePO), Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine, Epalinges 1066, Switzerland.,National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne (ISREC-EPFL), Lausanne 1015, Switzerland
| | - Christof B Wyss
- Experimental and Translational Oncology, Pathology Unit, Department of Oncology Microbiology and Immunology (OMI), Faculty of Science and Medicine, University of Fribourg, Fribourg 1700, Switzerland
| | - François Kuonen
- Division of Experimental Oncology, Multidisciplinary Oncology Center (CePO), Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine, Epalinges 1066, Switzerland.,National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne (ISREC-EPFL), Lausanne 1015, Switzerland
| | - Nicola Vannini
- Ludwig Institute for Cancer Research (LICR), Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Epalinges 1066, Switzerland
| | | | - Nathalie Duffey
- Experimental and Translational Oncology, Pathology Unit, Department of Oncology Microbiology and Immunology (OMI), Faculty of Science and Medicine, University of Fribourg, Fribourg 1700, Switzerland
| | - Raphael Pineau
- INSERM U1029 and University of Bordeaux, Pessac Cedex 33615, France
| | - Qiang Lan
- Experimental and Translational Oncology, Pathology Unit, Department of Oncology Microbiology and Immunology (OMI), Faculty of Science and Medicine, University of Fribourg, Fribourg 1700, Switzerland.,Division of Experimental Oncology, Multidisciplinary Oncology Center (CePO), Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine, Epalinges 1066, Switzerland.,National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne (ISREC-EPFL), Lausanne 1015, Switzerland
| | - Pratyaksha Wirapati
- Bioinformatics Core Facility, Swiss Institute for Bioinformatics (SIB), Lausanne 1015, Switzerland
| | - David Barras
- Bioinformatics Core Facility, Swiss Institute for Bioinformatics (SIB), Lausanne 1015, Switzerland
| | - Alessandro Tancredi
- Experimental and Translational Oncology, Pathology Unit, Department of Oncology Microbiology and Immunology (OMI), Faculty of Science and Medicine, University of Fribourg, Fribourg 1700, Switzerland
| | - Ruth Lyck
- Theodor Kocher Institute, University of Bern (UNIBE), Bern 3012, Switzerland
| | - Hans-Anton Lehr
- Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne 1011, Switzerland
| | - Britta Engelhardt
- Theodor Kocher Institute, University of Bern (UNIBE), Bern 3012, Switzerland
| | - Mauro Delorenzi
- Bioinformatics Core Facility, Swiss Institute for Bioinformatics (SIB), Lausanne 1015, Switzerland
| | - Andreas Bikfalvi
- INSERM U1029 and University of Bordeaux, Pessac Cedex 33615, France
| | - Curzio Rüegg
- Experimental and Translational Oncology, Pathology Unit, Department of Oncology Microbiology and Immunology (OMI), Faculty of Science and Medicine, University of Fribourg, Fribourg 1700, Switzerland.,Division of Experimental Oncology, Multidisciplinary Oncology Center (CePO), Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine, Epalinges 1066, Switzerland.,National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne (ISREC-EPFL), Lausanne 1015, Switzerland
| |
Collapse
|
9
|
Kechrid N, Tonellotto L, Monnier S, Rossi SA, Ulrich F, Kuonen F. Ex vivo confocal microscopy for the intraoperative assessment of deep margins in giant basal cell carcinoma. JAAD Case Rep 2022; 27:41-45. [PMID: 35996442 PMCID: PMC9391502 DOI: 10.1016/j.jdcr.2022.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Affiliation(s)
- Nebiha Kechrid
- Department of Dermatology and Venereology, Hôpital de Beaumont, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Luca Tonellotto
- Department of Dermatology and Venereology, Hôpital de Beaumont, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Sandra Monnier
- Department of Plastic and Reconstructive Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Severin A Rossi
- Department of Plastic and Reconstructive Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Franzisca Ulrich
- Department of Plastic and Reconstructive Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - François Kuonen
- Department of Dermatology and Venereology, Hôpital de Beaumont, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| |
Collapse
|
10
|
Yerly L, Pich-Bavastro C, Di Domizio J, Wyss T, Tissot-Renaud S, Cangkrama M, Gilliet M, Werner S, Kuonen F. Integrated multi-omics reveals cellular and molecular interactions governing the invasive niche of basal cell carcinoma. Nat Commun 2022; 13:4897. [PMID: 35986012 PMCID: PMC9391376 DOI: 10.1038/s41467-022-32670-w] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 08/11/2022] [Indexed: 11/23/2022] Open
Abstract
Tumors invade the surrounding tissues to progress, but the heterogeneity of cell types at the tumor-stroma interface and the complexity of their potential interactions hampered mechanistic insight required for efficient therapeutic targeting. Here, combining single-cell and spatial transcriptomics on human basal cell carcinomas, we define the cellular contributors of tumor progression. In the invasive niche, tumor cells exhibit a collective migration phenotype, characterized by the expression of cell-cell junction complexes. In physical proximity, we identify cancer-associated fibroblasts with extracellular matrix-remodeling features. Tumor cells strongly express the cytokine Activin A, and increased Activin A-induced gene signature is found in adjacent cancer-associated fibroblast subpopulations. Altogether, our data identify the cell populations and their transcriptional reprogramming contributing to the spatial organization of the basal cell carcinoma invasive niche. They also demonstrate the power of integrated spatial and single-cell multi-omics to decipher cancer-specific invasive properties and develop targeted therapies. The role of reciprocal tumour-stroma interactions in tumour invasion remains poorly characterised. Here, single-cell and spatial transcriptomics identifies the cell populations and their transcriptional reprogramming contributing to the spatial organization of the basal cell carcinoma invasive niche.
Collapse
|
11
|
Bartl J, Zanini M, Bernardi F, Forget A, Blümel L, Talbot J, Picard D, Qin N, Cancila G, Gao Q, Nath S, Koumba IM, Wolter M, Kuonen F, Langini M, Beez T, Munoz C, Pauck D, Marquardt V, Yu H, Souphron J, Korsch M, Mölders C, Berger D, Göbbels S, Meyer FD, Scheffler B, Rotblat B, Diederichs S, Ramaswamy V, Suzuki H, Oro A, Stühler K, Stefanski A, Fischer U, Leprivier G, Willbold D, Steger G, Buell A, Kool M, Lichter P, Pfister SM, Northcott PA, Taylor MD, Borkhardt A, Reifenberger G, Ayrault O, Remke M. The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. Nat Commun 2022; 13:4061. [PMID: 35831316 PMCID: PMC9279496 DOI: 10.1038/s41467-022-31574-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 06/20/2022] [Indexed: 11/24/2022] Open
Abstract
Most lncRNAs display species-specific expression patterns suggesting that animal models of cancer may only incompletely recapitulate the regulatory crosstalk between lncRNAs and oncogenic pathways in humans. Among these pathways, Sonic Hedgehog (SHH) signaling is aberrantly activated in several human cancer entities. We unravel that aberrant expression of the primate-specific lncRNA HedgeHog Interacting Protein-AntiSense 1 (HHIP-AS1) is a hallmark of SHH-driven tumors including medulloblastoma and atypical teratoid/rhabdoid tumors. HHIP-AS1 is actively transcribed from a bidirectional promoter shared with SHH regulator HHIP. Knockdown of HHIP-AS1 induces mitotic spindle deregulation impairing tumorigenicity in vitro and in vivo. Mechanistically, HHIP-AS1 binds directly to the mRNA of cytoplasmic dynein 1 intermediate chain 2 (DYNC1I2) and attenuates its degradation by hsa-miR-425-5p. We uncover that neither HHIP-AS1 nor the corresponding regulatory element in DYNC1I2 are evolutionary conserved in mice. Taken together, we discover an lncRNA-mediated mechanism that enables the pro-mitotic effects of SHH pathway activation in human tumors. Long non-coding RNAs (lncRNAs) can contribute to cancers that are driven by Sonic hedgehog (SHH) signaling. Here the authors report that lncRNA HHIP-AS1 stabilises the mRNA of dynein complex 1, thereby, promoting the pro-mitotic effects of SHH-driven tumors.
Collapse
Affiliation(s)
- Jasmin Bartl
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany. .,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany. .,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany. .,Group for Interdisciplinary Neurobiology and Immunology-INI-research, Institute of Zoology University of Hamburg, Hamburg, Germany.
| | - Marco Zanini
- Institut Curie, PSL Research University, CNRS UMR, INSERM, Orsay, France.,Université Paris Sud, Université Paris-Saclay, CNRS UMR, INSERM U, Orsay, France
| | - Flavia Bernardi
- Institut Curie, PSL Research University, CNRS UMR, INSERM, Orsay, France.,Université Paris Sud, Université Paris-Saclay, CNRS UMR, INSERM U, Orsay, France
| | - Antoine Forget
- Institut Curie, PSL Research University, CNRS UMR, INSERM, Orsay, France.,Université Paris Sud, Université Paris-Saclay, CNRS UMR, INSERM U, Orsay, France
| | - Lena Blümel
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Julie Talbot
- Institut Curie, PSL Research University, CNRS UMR, INSERM, Orsay, France.,Université Paris Sud, Université Paris-Saclay, CNRS UMR, INSERM U, Orsay, France
| | - Daniel Picard
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Nan Qin
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Gabriele Cancila
- Institut Curie, PSL Research University, CNRS UMR, INSERM, Orsay, France.,Université Paris Sud, Université Paris-Saclay, CNRS UMR, INSERM U, Orsay, France
| | - Qingsong Gao
- St Jude Children's Research Hospital, Memphis, TN, USA
| | - Soumav Nath
- Institut für Physikalische Biologie and Biological-Medical Research Center (BMFZ), Heinrich Heine University, Düsseldorf, Germany.,IBI- (Strukturbiochemie) and JuStruct, Forschungszentrum Jülich, Jülich, Germany
| | - Idriss Mahoungou Koumba
- Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Marietta Wolter
- Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - François Kuonen
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.,Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, CH- Lausanne, Lausanne, Switzerland
| | - Maike Langini
- Institute for Molecular Medicine, Proteome Research, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - Thomas Beez
- Department of Neurosurgery, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - Christopher Munoz
- Department of Neurosurgery, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - David Pauck
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Viktoria Marquardt
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Hua Yu
- Institut Curie, PSL Research University, CNRS UMR, INSERM, Orsay, France.,Université Paris Sud, Université Paris-Saclay, CNRS UMR, INSERM U, Orsay, France
| | - Judith Souphron
- Institut Curie, PSL Research University, CNRS UMR, INSERM, Orsay, France.,Université Paris Sud, Université Paris-Saclay, CNRS UMR, INSERM U, Orsay, France
| | - Mascha Korsch
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Christina Mölders
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Daniel Berger
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Sarah Göbbels
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Frauke-Dorothee Meyer
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Björn Scheffler
- DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ), DKTK, partner site University Hospital Essen, Düsseldorf, Germany
| | - Barak Rotblat
- Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.,The National Institute for Biotechnology in the Negev, Beer Sheva, Israel
| | - Sven Diederichs
- Division of Cancer Research, Department of Thoracic Surgery, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, DKTK, partner site Freiburg, Freiburg i.Br, Germany.,Division of RNA Biology & Cancer, DKFZ, Heidelberg, Germany
| | - Vijay Ramaswamy
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Division of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Hiromishi Suzuki
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Anthony Oro
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.,Department of Dermatology, Stanford University, Stanford, CA, USA
| | - Kai Stühler
- Molecular Proteomics Laboratory (MPL), BMFZ, Heinrich Heine University, Düsseldorf, Germany
| | - Anja Stefanski
- Molecular Proteomics Laboratory (MPL), BMFZ, Heinrich Heine University, Düsseldorf, Germany
| | - Ute Fischer
- Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Gabriel Leprivier
- Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Dieter Willbold
- Institut für Physikalische Biologie and Biological-Medical Research Center (BMFZ), Heinrich Heine University, Düsseldorf, Germany.,IBI- (Strukturbiochemie) and JuStruct, Forschungszentrum Jülich, Jülich, Germany
| | - Gerhard Steger
- Institut für Physikalische Biologie and Biological-Medical Research Center (BMFZ), Heinrich Heine University, Düsseldorf, Germany
| | - Alexander Buell
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Marcel Kool
- Hopp Children´s Cancer Center (KiTZ), Heidelberg, Germany.,Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.,Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - Peter Lichter
- Division of Molecular Genetics, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), and National Center for Tumor Diseases (NCT), Heidelberg, Germany
| | - Stefan M Pfister
- Hopp Children´s Cancer Center (KiTZ), Heidelberg, Germany.,Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.,Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
| | | | - Michael D Taylor
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.,Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Arndt Borkhardt
- Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Guido Reifenberger
- Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Olivier Ayrault
- Institut Curie, PSL Research University, CNRS UMR, INSERM, Orsay, France. .,Université Paris Sud, Université Paris-Saclay, CNRS UMR, INSERM U, Orsay, France.
| | - Marc Remke
- Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany. .,Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, and DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany. .,Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany, DKTK, partner site Essen/Düsseldorf, Düsseldorf, Germany.
| |
Collapse
|
12
|
Grizzetti L, Kuonen F. Ex vivo confocal microscopy for surgical margin assessment: A histology-compared study on 109 specimens. Skin Health Dis 2022; 2:e91. [PMID: 35677928 PMCID: PMC9168011 DOI: 10.1002/ski2.91] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Revised: 12/29/2021] [Accepted: 12/30/2021] [Indexed: 12/13/2022]
Abstract
Background The assessment of surgical margins is mandatory to prevent local recurrence or distant dissemination of skin cancers. Histological examination of haematoxylin and eosin (H&E)-stained slides from paraffin-embedded or frozen samples is the gold standard for margin assessment, but is a time-consuming procedure. Ex vivo confocal laser scanning microscopy (CLSM) is an upcoming technique that scans unfixed fresh tissue rapidly, allowing fast per-operative margin assessment. Objective Here, we propose to assess the efficiency of a new ex vivo confocal microscope for the per-operative assessment of surgical margins. Methods We analyzed 16 biopsies and 93 surgical specimens of basal cell and squamous cell carcinomas by ex vivo CLSM using Histolog® Scanner V2. Surgical specimens included fusiform excisions, slow-Mohs peripheral and deep compartments, and Mohs excisions. The time required from surgical excision to image analysis was recorded and the quality of the images obtained for each specimen assessed. The presence or absence of tumour was estimated based on ex vivo CLSM images and compared with conventional H&E-stained sections from paraffin-embedded or frozen (Mohs) specimens. Results Mean time for specimen processing using Histolog Scanner was 5.1 ± 3.4 min. We obtained 89% of high quality images. Mean time for confocal image analysis was 1 ± 0.76 min. The diagnostic sensitivity and specificity for ex vivo CLSM compared to classical H&E procedures were respectively 93% and 100% when performed on tumour biopsies. The overall sensitivity and specificity for ex vivo CLSM for margin assessment compared to classical H&E procedures were respectively 61.5% and 95%, with variations depending on the type of tumour or surgical specimen analyzed. In particular, we obtained 80% sensitivity and 100% specificity for the assessment of BCC surgical margins. Conclusion Our data suggest that ex vivo CLSM using Histolog® Scanner V2 could be a valid help for surgeons for a fast and accurate per-operative margin analysis.
Collapse
Affiliation(s)
- L. Grizzetti
- Department of Dermatology and Venereology, Hôpital de BeaumontLausanne University Hospital CenterLausanneSwitzerland
| | - F. Kuonen
- Department of Dermatology and Venereology, Hôpital de BeaumontLausanne University Hospital CenterLausanneSwitzerland
| |
Collapse
|
13
|
Capolupo L, Khven I, Lederer AR, Mazzeo L, Glousker G, Ho S, Russo F, Montoya JP, Bhandari DR, Bowman AP, Ellis SR, Guiet R, Burri O, Detzner J, Muthing J, Homicsko K, Kuonen F, Gilliet M, Spengler B, Heeren RMA, Dotto GP, La Manno G, D'Angelo G. Sphingolipids control dermal fibroblast heterogeneity. Science 2022; 376:eabh1623. [PMID: 35420948 DOI: 10.1126/science.abh1623] [Citation(s) in RCA: 52] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Human cells produce thousands of lipids that change during cell differentiation and can vary across individual cells of the same type. However, we are only starting to characterize the function of these cell-to-cell differences in lipid composition. Here, we measured the lipidomes and transcriptomes of individual human dermal fibroblasts by coupling high-resolution mass spectrometry imaging with single-cell transcriptomics. We found that the cell-to-cell variations of specific lipid metabolic pathways contribute to the establishment of cell states involved in the organization of skin architecture. Sphingolipid composition is shown to define fibroblast subpopulations, with sphingolipid metabolic rewiring driving cell-state transitions. Therefore, cell-to-cell lipid heterogeneity affects the determination of cell states, adding a new regulatory component to the self-organization of multicellular systems.
Collapse
Affiliation(s)
- Laura Capolupo
- Interfaculty Institute of Bioengineering and Global Health Institute, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
| | - Irina Khven
- Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
| | - Alex R Lederer
- Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
| | - Luigi Mazzeo
- Department of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland
| | - Galina Glousker
- School of Life Sciences, Swiss Institute for Experimental Cancer Research, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
| | - Sylvia Ho
- Interfaculty Institute of Bioengineering and Global Health Institute, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
| | - Francesco Russo
- Institute of Biochemistry and Cellular Biology, National Research Council of Italy, 80131 Napoli, Italy
| | - Jonathan Paz Montoya
- Interfaculty Institute of Bioengineering and Global Health Institute, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
| | - Dhaka R Bhandari
- Institute for Inorganic and Analytical Chemistry, Justus Liebig University Giessen, 35392 Giessen, Germany
| | - Andrew P Bowman
- Maastricht MultiModal Molecular Imaging Institute, Division of Imaging Mass Spectrometry, Maastricht University, 6629 ER Maastricht, Netherlands
| | - Shane R Ellis
- Maastricht MultiModal Molecular Imaging Institute, Division of Imaging Mass Spectrometry, Maastricht University, 6629 ER Maastricht, Netherlands.,Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, New South Wales 2522, Australia.,Illawarra Health and Medical Research Institute, Wollongong, New South Wales 2522, Australia
| | - Romain Guiet
- Faculté des Sciences de la Vie, Bioimaging and Optics Platform, École Polytechnique Fédérale de Lausanne, Lausanne, CH-1015 Vaud, Switzerland
| | - Olivier Burri
- Faculté des Sciences de la Vie, Bioimaging and Optics Platform, École Polytechnique Fédérale de Lausanne, Lausanne, CH-1015 Vaud, Switzerland
| | - Johanna Detzner
- Institute of Hygiene, University of Münster, D-48149 Münster, Germany
| | - Johannes Muthing
- Institute of Hygiene, University of Münster, D-48149 Münster, Germany
| | - Krisztian Homicsko
- Department of Oncology, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland.,Swiss Cancer Center Leman, CH-1015 Lausanne, Switzerland.,The Ludwig Institute for Cancer Research, Lausanne Branch, CH-1066 Epalinges, Switzerland
| | - François Kuonen
- Département de Dermatologie et Vénéréologie, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland
| | - Michel Gilliet
- Département de Dermatologie et Vénéréologie, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland
| | - Bernhard Spengler
- Institute for Inorganic and Analytical Chemistry, Justus Liebig University Giessen, 35392 Giessen, Germany
| | - Ron M A Heeren
- Maastricht MultiModal Molecular Imaging Institute, Division of Imaging Mass Spectrometry, Maastricht University, 6629 ER Maastricht, Netherlands
| | - G Paolo Dotto
- Personalized Cancer Prevention Research Unit, Head and Neck Surgery Division, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland.,Department of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland.,Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, MA 02129, USA
| | - Gioele La Manno
- Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
| | - Giovanni D'Angelo
- Interfaculty Institute of Bioengineering and Global Health Institute, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.,Institute of Biochemistry and Cellular Biology, National Research Council of Italy, 80131 Napoli, Italy
| |
Collapse
|
14
|
Koulouri A, Buset C, Hafner J, Kuonen F. [Management of chronic ulcers: punch grafting]. Rev Med Suisse 2022; 18:604-607. [PMID: 35353456 DOI: 10.53738/revmed.2022.18.775.604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Chronic ulcers are a common but important dermatological problem and a major source of expense in the western countries. Skin graft is a surgical procedure in which skin or skin substitute is transplanted in order to close a wound. This article aims to review the different categories of grafts, their indications for the healing of chronic ulcers of the lower limbs, emphasizing the position of punch grafts in the treatment arsenal.
Collapse
Affiliation(s)
- Angeliki Koulouri
- Service de dermatologie et vénéréologie, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Caroline Buset
- Service de dermatologie, Hôpital universitaire de Bâle, 4031 Bâle
| | - Jürg Hafner
- Service de dermatologie, Hôpital universitaire de Zurich, 8058 Zurich
| | - François Kuonen
- Service de dermatologie et vénéréologie, Centre hospitalier universitaire vaudois, 1011 Lausanne
| |
Collapse
|
15
|
Zahn CA, Kuonen F. A Closure Option for Combination Defects of the Nasal Sidewall and Paranasal Cheek. Dermatol Surg 2021; 47:1626-1628. [PMID: 32541341 DOI: 10.1097/dss.0000000000002477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Carole Anouk Zahn
- Both authors are affiliated with the Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| | | |
Collapse
|
16
|
Kuonen F, Li NY, Haensel D, Patel T, Gaddam S, Yerly L, Rieger K, Aasi S, Oro AE. c-FOS drives reversible basal to squamous cell carcinoma transition. Cell Rep 2021; 37:109774. [PMID: 34610301 PMCID: PMC8515919 DOI: 10.1016/j.celrep.2021.109774] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 06/28/2021] [Accepted: 09/08/2021] [Indexed: 01/22/2023] Open
Abstract
While squamous transdifferentiation within subpopulations of adenocarcinomas represents an important drug resistance problem, its underlying mechanism remains poorly understood. Here, using surface markers of resistant basal cell carcinomas (BCCs) and patient single-cell and bulk transcriptomic data, we uncover the dynamic roadmap of basal to squamous cell carcinoma transition (BST). Experimentally induced BST identifies activator protein 1 (AP-1) family members in regulating tumor plasticity, and we show that c-FOS plays a central role in BST by regulating the accessibility of distinct AP-1 regulatory elements. Remarkably, despite prominent changes in cell morphology and BST marker expression, we show using inducible model systems that c-FOS-mediated BST demonstrates reversibility. Blocking EGFR pathway activation after c-FOS induction partially reverts BST in vitro and prevents BST features in both mouse models and human tumors. Thus, by identifying the molecular basis of BST, our work reveals a therapeutic opportunity targeting plasticity as a mechanism of tumor resistance.
Collapse
MESH Headings
- Animals
- Carcinoma, Basal Cell/metabolism
- Carcinoma, Basal Cell/pathology
- Carcinoma, Basal Cell/veterinary
- Carcinoma, Squamous Cell/metabolism
- Carcinoma, Squamous Cell/pathology
- Carcinoma, Squamous Cell/veterinary
- Cell Transdifferentiation/drug effects
- Chromatin Assembly and Disassembly
- Drug Resistance, Neoplasm/genetics
- Humans
- Male
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Mucin-1/metabolism
- Protein Kinase Inhibitors/pharmacology
- Proto-Oncogene Proteins c-fos/antagonists & inhibitors
- Proto-Oncogene Proteins c-fos/genetics
- Proto-Oncogene Proteins c-fos/metabolism
- RNA Interference
- RNA, Small Interfering/metabolism
- Signal Transduction/drug effects
- Transcription Factor AP-1/metabolism
- Transforming Growth Factor beta/antagonists & inhibitors
- Transforming Growth Factor beta/genetics
- Transforming Growth Factor beta/metabolism
- ras Proteins/genetics
- ras Proteins/metabolism
Collapse
Affiliation(s)
- François Kuonen
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA; Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, 1011 Lausanne, Switzerland.
| | - Nancy Yanzhe Li
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - Daniel Haensel
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - Tiffany Patel
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - Sadhana Gaddam
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - Laura Yerly
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, 1011 Lausanne, Switzerland
| | - Kerri Rieger
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - Sumaira Aasi
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - Anthony E Oro
- Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.
| |
Collapse
|
17
|
Di Domizio J, Baldo A, Yatim A, Vandenberghe-Dürr S, Jenelten R, Fries A, Grizzetti L, Kuonen F, Modlin R, Paul C, Conrad C, Gilliet M. 189 Interleukin (IL)-26 drives pustular forms of psoriasis by linking neutrophils to keratinocyte activation. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Kuonen F, Li N, Haensel D, Patel T, Gaddam S, Yerly L, Rieger K, Aasi S, Oro A. 249 C-FOS drives reversible basal to squamous cell carcinoma transition. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Zahn CA, Kuonen F. Deep Breathing Reduces Intraoperative Anxiety and Pain Perception in Patients Undergoing Dermatologic Surgery. Dermatol Surg 2021; 47:1137-1139. [PMID: 33587376 DOI: 10.1097/dss.0000000000002891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Carole A Zahn
- Both authors are affiliated with the Department of Dermatology, CHUV, Lausanne, Switzerland
| | | |
Collapse
|
20
|
Kuonen F, Li N, Haensel D, Patel T, Gaddam S, Yerly L, Rieger K, Aasi S, Oro A. 065 C-FOS drives reversible basal to squamous cell carcinoma transition. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
21
|
Lorusso G, Rüegg C, Kuonen F. Targeting the Extra-Cellular Matrix-Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors. Front Oncol 2020; 10:1231. [PMID: 32793493 PMCID: PMC7387567 DOI: 10.3389/fonc.2020.01231] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Accepted: 06/16/2020] [Indexed: 12/11/2022] Open
Abstract
The extracellular matrix (ECM) is a complex network composed of a multitude of different macromolecules. ECM components typically provide a supportive structure to the tissue and engender positional information and crosstalk with neighboring cells in a dynamic reciprocal manner, thereby regulating tissue development and homeostasis. During tumor progression, tumor cells commonly modify and hijack the surrounding ECM to sustain anchorage-dependent growth and survival, guide migration, store pro-tumorigenic cell-derived molecules and present them to enhance receptor activation. Thereby, ECM potentially supports tumor progression at various steps from initiation, to local growth, invasion, and systemic dissemination and ECM-tumor cells interactions have long been considered promising targets for cancer therapy. Integrins represent key surface receptors for the tumor cell to sense and interact with the ECM. Yet, attempts to therapeutically impinge on these interactions using integrin inhibitors have failed to deliver anticipated results, and integrin inhibitors are still missing in the emerging arsenal of drugs for targeted therapies. This paradox situation should urge the field to reconsider the role of integrins in cancer and their targeting, but also to envisage alternative strategies. Here, we review the therapeutic targets implicated in tumor cell adhesion to the ECM, whose inhibitors are currently in clinical trials and may offer alternatives to integrin inhibition.
Collapse
Affiliation(s)
- Girieca Lorusso
- Experimental and Translational Oncology, Department of Oncology Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
| | - Curzio Rüegg
- Experimental and Translational Oncology, Department of Oncology Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
| | - François Kuonen
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| |
Collapse
|
22
|
Grizzetti L, Gaide O, Kuonen F. [Dermatofibrosarcoma protuberans : clinico-pathological aspects and management]. Rev Med Suisse 2020; 16:640-645. [PMID: 32239838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The dermatofibrosarcoma protuberans (DFSP) is the most common form of low-grade cutaneous sarcoma; its infiltrating growth occurs by fingerlike projections, which explain the high rate of recurrence in case of inappropriate surgical procedure. Based on an extensive review of the existing literature, we propose here to discuss the actual criteria for early recognition, diagnosis and optimal take of care of DFSP.
Collapse
Affiliation(s)
| | - Olivier Gaide
- Département de dermatologie et vénéréologie, CHUV, 1011 Lausanne
| | - François Kuonen
- Département de dermatologie et vénéréologie, CHUV, 1011 Lausanne
| |
Collapse
|
23
|
Chiang A, Tan C, Kuonen F, Hodgkinson L, Chiang F, Cho R, Tang J, Chang A, Rieger K, Oro A, Sarin K. 471 Genetic mutations underlying phenotypic plasticity in basosquamous carcinoma. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Chiang A, Tan CZ, Kuonen F, Hodgkinson LM, Chiang F, Cho RJ, South AP, Tang JY, Chang ALS, Rieger KE, Oro AE, Sarin KY. Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma. J Invest Dermatol 2019; 139:2263-2271.e5. [PMID: 31207229 DOI: 10.1016/j.jid.2019.03.1163] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2018] [Revised: 03/02/2019] [Accepted: 03/19/2019] [Indexed: 12/30/2022]
Abstract
Basosquamous carcinoma (BSC) is an aggressive skin neoplasm with the features of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). While genetic drivers of BCC and SCC development have been extensively characterized, BSC has not been well studied, and it remains unclear whether these tumors originally derive from BCC or SCC. In addition, it is unknown which molecular pathways mediate the reprogramming of tumor keratinocytes toward basaloid or squamatized phenotypes. We sought to characterize the genomic alterations underlying sporadic BSC to elucidate the derivation of these mixed tumors. We identifed frequent Hedgehog (Hh) pathway mutations in BSCs, implicating Hh deregulation as the primary driving event in BSC. Principal component analysis of BCC and SCC driver genes further demonstrate the genetic similarity between BCC and BSC. In addition, 45% of the BSCs harbor recurrent mutations in the SWI/SNF complex gene, ARID1A, and evolutionary analysis revealed that ARID1A mutations occur after PTCH1 but before SCC driver mutations, indicating that ARID1A mutations may bestow plasticity enabling squamatization. Finally, we demonstrate mitogen-activated protein kinase pathway activation and the loss of Hh signaling associated with the squamatization of BSCs. Overall, these results support the genetic derivation of BSCs from BCCs and highlight potential factors involved in modulating tumor reprogramming between basaloid and squamatized phenotypes.
Collapse
Affiliation(s)
- Audris Chiang
- Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA; University of California, Irvine School of Medicine, Irvine, California, USA
| | - Caroline Z Tan
- Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - François Kuonen
- Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Luqman M Hodgkinson
- Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Felicia Chiang
- Department of Civil and Environmental Engineering, University of California, Irvine, Irvine, California, USA
| | - Raymond J Cho
- Department of Dermatology, University of California, San Francisco, San Francisco, California, USA
| | - Andrew P South
- Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - Jean Y Tang
- Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Anne Lynn S Chang
- Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Kerri E Rieger
- Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Anthony E Oro
- Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Kavita Y Sarin
- Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
| |
Collapse
|
25
|
Koulouri A, Kuonen F, Gaide O. [Artificial intelligence and the skin specialist]. Rev Med Suisse 2019; 15:687-691. [PMID: 30916908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Artificial intelligence's progress is spread on front pages of both lay and scientific journals. After Chess, after Go, before Dota2 and Starcraft, super-trained softwares have equaled or out-performed dermatologists. But what is the future of these computer programs and how will they change clinical practice for both the general practitioner and the skin specialist? It is time to ask these questions, even though the promises of these new technologies are not yet available.
Collapse
Affiliation(s)
- Angeliki Koulouri
- Service de dermatologie et vénéréologie, Hôpital de Beaumont, CHUV, 1011 Lausanne
| | - François Kuonen
- Service de dermatologie et vénéréologie, Hôpital de Beaumont, CHUV, 1011 Lausanne
| | - Olivier Gaide
- Service de dermatologie et vénéréologie, Hôpital de Beaumont, CHUV, 1011 Lausanne
| |
Collapse
|
26
|
Kuonen F, Huskey NE, Shankar G, Jaju P, Whitson RJ, Rieger KE, Atwood SX, Sarin KY, Oro AE. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. J Invest Dermatol 2019; 139:1439-1448. [PMID: 30707899 DOI: 10.1016/j.jid.2018.11.035] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Revised: 11/08/2018] [Accepted: 11/09/2018] [Indexed: 12/20/2022]
Abstract
Basal cell carcinomas (BCCs) rely on Hedgehog (HH) pathway growth signal amplification by the microtubule-based organelle, the primary cilium. Despite naive tumor responsiveness to Smoothened inhibitors (Smoi), resistance in advanced tumors remains common. Although the resistant BCCs usually maintain HH pathway activation, squamous cell carcinomas with Ras/MAPK pathway activation also arise, and the molecular basis of tumor type and pathway selection are still obscure. Here, we identify the primary cilium as a critical determinant controlling tumor pathway switching. Strikingly, Smoothened inhibitor-resistant BCCs have an increased mutational load in ciliome genes, resulting in reduced primary cilia and HH pathway activation compared with naive or Gorlin syndrome patient BCCs. Gene set enrichment analysis of resistant BCCs with a low HH pathway signature showed increased Ras/MAPK pathway activation. Tissue analysis confirmed an inverse relationship between primary cilia presence and Ras/MAPK activation, and primary cilia removal in BCCs potentiated Ras/MAPK pathway activation. Moreover, activating Ras in HH-responsive cell lines conferred resistance to both canonical (vismodegib) and noncanonical (atypical protein kinase C and MRTF inhibitors) HH pathway inhibitors and conferred sensitivity to MAPK inhibitors. Our results provide insights into BCC treatment and identify the primary cilium as an important lineage gatekeeper, preventing HH-to-Ras/MAPK pathway switching.
Collapse
Affiliation(s)
- François Kuonen
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Noelle E Huskey
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Gautam Shankar
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Prajakta Jaju
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Ramon J Whitson
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Kerri E Rieger
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Scott X Atwood
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Kavita Y Sarin
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Anthony E Oro
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
| |
Collapse
|
27
|
Cunha N, Fattouh K, Frings V, Hernandez-Aragues I, Stembridge N, Kuonen F. What's new this month? Eur J Dermatol 2018; 28:856-857. [PMID: 30698151 DOI: 10.1684/ejd.2018.3465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Nélia Cunha
- Dermatology Department, Hospital de Santo António dos Capuchos - Centro Hospitalar de Lisboa Central, Lisboa, Portugal
| | - Kinda Fattouh
- Dermatology Department, Hôpital Edouard Herriot, Lyon, France
| | - Verena Frings
- Department of Dermatology, Venerology and Allergology, University Hospital Wuerzburg, Josef-Schneider-Str. 2, 97080 Wuerzburg, Germany
| | | | - Natasha Stembridge
- Dermatology Department, Addenbrookes Hospital, Hills Road, Cambridge, UK
| | - François Kuonen
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Av. de Beaumont 29, CH-1011 Lausanne, Switzerland
| |
Collapse
|
28
|
Stembridge N, Cunha N, Fattouh K, Frings V, Hernandez-Aragues I, Kuonen F. What's new this month? Eur J Dermatol 2018; 28:722-723. [PMID: 30530436 DOI: 10.1684/ejd.2018.3418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Natasha Stembridge
- Dermatology Department, Addenbrookes Hospital, Hills Road, Cambridge, UK
| | - Nélia Cunha
- Dermatology Department, Hospital de Santo António dos Capuchos-Centro Hospitalar de Lisboa Central, Lisboa, Portugal
| | - Kinda Fattouh
- Dermatology Department, Hôpital Edouard Herriot, Lyon, France
| | - Verena Frings
- Department of Dermatology, Venereology and Allergology, University Hospital Wuerzburg, Joseph-Schneider- Str. 2, 97080 Wuerzburg, Germany
| | | | - François Kuonen
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Av. de Beaumont 29, CH-1011 Lausanne, Switzerland
| |
Collapse
|
29
|
Kuonen F, Surbeck I, Sarin KY, Dontenwill M, Rüegg C, Gilliet M, Oro AE, Gaide O. TGFβ, Fibronectin and Integrin α5β1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 2018; 138:2432-2442. [PMID: 29758283 DOI: 10.1016/j.jid.2018.04.029] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Revised: 04/20/2018] [Accepted: 04/25/2018] [Indexed: 12/13/2022]
Abstract
Basal cell carcinoma (BCC) is the most frequent human cancer and is becoming an important health problem in an aging population. Based on their clinical and histological characteristics, thick BCC are typically divided into low-risk nodular and high-risk infiltrative subtypes, although the underlying mechanisms are poorly understood. We have identified molecular mechanisms that explain the aggressiveness of high-risk infiltrative BCC, with a potential direct clinical impact. In this study, we first show that fibroblasts, transforming growth factor-β, and fibronectin are found preferentially in infiltrative human BCC. This allowed us to develop in vivo models for the study of infiltrative BCC, which in turn let us confirm the role of transforming growth factor-β in inducing peritumoral fibronectin deposition and tumor infiltration. We then show that fibronectin promotes adhesion and migration of BCC cell lines through integrin α5β1-mediated phosphorylation of focal adhesion kinase. Fittingly, both inhibition of integrin α5β1 and phospho-focal adhesion kinase prevent fibronectin-induced migration of BCC cells in vitro as well as BCC infiltration in vivo. Altogether, our results open important insights into the pathogenesis of aggressive infiltrative BCC and identify integrin α5β1 or focal adhesion kinase inhibition as promising strategies for the treatment of advanced BCC.
Collapse
Affiliation(s)
- François Kuonen
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland; Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
| | - Isabelle Surbeck
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| | - Kavita Y Sarin
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Monique Dontenwill
- Laboratory of Biophotonic and Pharmacology, UMR7213 CNRS, University of Strasbourg, Strasbourg, France
| | - Curzio Rüegg
- Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland
| | - Michel Gilliet
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| | - Anthony E Oro
- Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
| | - Olivier Gaide
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| |
Collapse
|
30
|
Kuonen F, Kuonen I, Dontenwill M, Rüegg C, Oro A, Gilliet M, Gaide O. 844 Identification of a novel pathway linking TGF-β, fibronectin and integrin α5β1 that promotes invasion in basal cell carcinoma. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
Kuonen F, Huskey N, Shankar G, Sarin K, Oro A. 221 BCC to SCC pathway switching during tumor evolution and the role of the primary cilium. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Kuonen F, Gilliet M, Perrier P. Non-Melanoma Skin Cancers of the Fronto-Temporal Area Preferentially Localize in the Proximity of Arterial Blood Vessels. Dermatology 2017; 233:199-204. [DOI: 10.1159/000468537] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 03/05/2017] [Indexed: 11/19/2022] Open
|
33
|
Dorsaz M, Kuonen F, Baroffio C. Current spotted wing drosophila IPM tactics and their practical implementation in berry crops in Switzerland. ACTA ACUST UNITED AC 2017. [DOI: 10.17660/actahortic.2017.1156.122] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
34
|
Kuonen F, Gaide O. Clues in DeRmoscopy: dermoscopy of angioma serpiginosum. Eur J Dermatol 2016; 26:118. [PMID: 27113009 DOI: 10.1684/ejd.2016.2754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- François Kuonen
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, CH-1011 Lausanne, Switzerland
| | - Olivier Gaide
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, CH-1011 Lausanne, Switzerland
| |
Collapse
|
35
|
Kuonen F, Gaide O. [New light on skin photodynamic therapy]. Rev Med Suisse 2014; 10:754-759. [PMID: 24772809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Photodynamic therapy (PDT) relies on the cellular toxicity of an exogenous porphyrin that is activated by light rays. Its specificity depends on its cellular uptake, which is typically high in cells with a high metabolism, such as cancer cells and several microbial pathogens. Both the diffusion of the substrate and the penetration of the light in the tissue limit its efficiency to the first few millimeters of the skin. This explains why this technique is used for the treatment of superficial skin cancers (actinic keratosis and basal cell carcinomas), but also for selected skin inflammatory diseases (psoriasis) or infections (leishmaniosis). However, at the bedside, the limitations of PDT are rather the complexity and the pain associated with the treatment. Herein, we present the new developments, in particular concerning the new light sources, which make PDT a better option for our patients.
Collapse
|
36
|
Kuonen F, Bucher M, de Leval L, Vernez M, Gilliet M, Conrad C, Feldmeyer L. Purpura of the face and neck: an atypical clinical presentation revealing a hepatosplenic T cell lymphoma. Case Rep Dermatol 2014; 6:37-42. [PMID: 24707248 PMCID: PMC3975201 DOI: 10.1159/000360126] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Background Hepatosplenic T cell lymphoma (HSTL) is a rare but very aggressive peripheral T cell lymphoma whose initial silent clinical presentation unfortunately delays the diagnosis and worsens the prognosis of patient survival. Efforts should be aimed at early recognition and treatment. Methods We describe a case of a 62-year-old woman who presented at our clinic with a non-palpable purpuric eruption of the face. Investigations revealed thrombocytopenia with hepatosplenomegaly, which showed rapid progression together with accentuation of the purpura. Two months later, a bone marrow biopsy revealed the diagnosis of a HSTL. Results The patient received six cycles of CHOP chemotherapy (vincristine, cyclophosphamide, doxorubicin, methylprednisolone) followed by a well-tolerated autologous bone marrow graft. Normalization of the platelet count resulted in regression of the purpuric rash. Conclusion To our knowledge, this is the first report of a facial thrombocytopenic purpura as the inaugural symptom of HSTL. It emphasizes the privileged position of the dermatologist for early recognition of potentially lethal HSTL.
Collapse
Affiliation(s)
- François Kuonen
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| | - Maya Bucher
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| | - Laurence de Leval
- Institute of Clinical Pathology, Lausanne University Hospital Center, Lausanne, Switzerland
| | - Maxime Vernez
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| | - Michel Gilliet
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| | - Curdin Conrad
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| | - Laurence Feldmeyer
- Department of Dermatology and Venereology, Hôpital de Beaumont, Lausanne University Hospital Center, Lausanne, Switzerland
| |
Collapse
|
37
|
Kuonen F, Laurent J, Secondini C, Lorusso G, Stehle JC, Rausch T, Faes-Van't Hull E, Bieler G, Alghisi GC, Schwendener R, Andrejevic-Blant S, Mirimanoff RO, Rüegg C. Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy. Clin Cancer Res 2012; 18:4365-74. [PMID: 22711708 DOI: 10.1158/1078-0432.ccr-11-3028] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
PURPOSE Local breast cancer relapse after breast-saving surgery and radiotherapy is associated with increased risk of distant metastasis formation. The mechanisms involved remain largely elusive. We used the well-characterized 4T1 syngeneic, orthotopic breast cancer model to identify novel mechanisms of postradiation metastasis. EXPERIMENTAL DESIGN 4T1 cells were injected in 20 Gy preirradiated mammary tissue to mimic postradiation relapses, or in nonirradiated mammary tissue, as control, of immunocompetent BALB/c mice. Molecular, biochemical, cellular, histologic analyses, adoptive cell transfer, genetic, and pharmacologic interventions were carried out. RESULTS Tumors growing in preirradiated mammary tissue had reduced angiogenesis and were more hypoxic, invasive, and metastatic to lung and lymph nodes compared with control tumors. Increased metastasis involved the mobilization of CD11b(+)c-Kit(+)Ly6G(high)Ly6C(low)(Gr1(+)) myeloid cells through the HIF1-dependent expression of Kit ligand (KitL) by hypoxic tumor cells. KitL-mobilized myeloid cells homed to primary tumors and premetastatic lungs, to give rise to CD11b(+)c-Kit(-) cells. Pharmacologic inhibition of HIF1, silencing of KitL expression in tumor cells, and inhibition of c-Kit with an anti-c-Kit-blocking antibody or with a tyrosine kinase inhibitor prevented the mobilization of CD11b(+)c-Kit(+) cells and attenuated metastasis. C-Kit inhibition was also effective in reducing mobilization of CD11b(+)c-Kit(+) cells and inhibiting lung metastasis after irradiation of established tumors. CONCLUSIONS Our work defines KitL/c-Kit as a previously unidentified axis critically involved in promoting metastasis of 4T1 tumors growing in preirradiated mammary tissue. Pharmacologic inhibition of this axis represents a potential therapeutic strategy to prevent metastasis in breast cancer patients with local relapses after radiotherapy.
Collapse
Affiliation(s)
- François Kuonen
- Department of Radio-Oncology, Centre Hospitalier Universitaire Vaudois, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Kuonen F, Secondini C, Rüegg C. Molecular Pathways: Emerging Pathways Mediating Growth, Invasion, and Metastasis of Tumors Progressing in an Irradiated Microenvironment. Clin Cancer Res 2012; 18:5196-202. [DOI: 10.1158/1078-0432.ccr-11-1758] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Laurent J, Touvrey C, Botta F, Kuonen F, Ruegg C. Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. Int J Dev Biol 2011; 55:527-34. [PMID: 21769777 DOI: 10.1387/ijdb.103228jl] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Cancer-related inflammation has emerged in recent years as a major event contributing to tumor angiogenesis, tumor progression and metastasis formation. Bone marrow-derived and inflammatory cells promote tumor angiogenesis by providing endothelial progenitor cells that differentiate into mature endothelial cells, and by secreting pro-angiogenic factors and remodeling the extracellular matrix to stimulate angiogenesis though paracrine mechanisms. Several bone marrow-derived myelonomocytic cells, including monocytes and macrophages, have been identified and characterized by several laboratories in recent years. While the central role of these cells in promoting tumor angiogenesis, tumor progression and metastasis is nowadays well established, many questions remain open and new ones are emerging. These include the relationship between their phenotype and function, the mechanisms of pro-angiogenic programming, their contribution to resistance to anti-angiogenic treatments and to metastasis and their potential clinical use as biomarkers of angiogenesis and anti-angiogenic therapies. Here, we will review phenotypical and functional aspects of bone marrow-derived myelonomocytic cells and discuss some of the current outstanding questions.
Collapse
Affiliation(s)
- Julien Laurent
- Centre Pluridiscipliniaire d'Oncologie, University of Lausanne, Lausanne, Switzerland
| | | | | | | | | |
Collapse
|
40
|
Laurent J, Hull EFV, Touvrey C, Kuonen F, Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC, Fagiani E, Zaman K, Stupp R, Shibuya M, Delaloye JF, Christofori G, Ruegg C. Proangiogenic Factor PlGF Programs CD11b+ Myelomonocytes in Breast Cancer during Differentiation of Their Hematopoietic Progenitors. Cancer Res 2011; 71:3781-91. [DOI: 10.1158/0008-5472.can-10-3684] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Tumor-mobilized bone marrow–derived CD11b+ myeloid cells promote tumor angiogenesis, but how and when these cells acquire proangiogenic properties is not fully elucidated. Here, we show that CD11b+ myelomonocytic cells develop proangiogenic properties during their differentiation from CD34+ hematopoietic progenitors and that placenta growth factor (PlGF) is critical in promoting this education. Cultures of human CD34+ progenitors supplemented with conditioned medium from breast cancer cell lines or PlGF, but not from nontumorigenic breast epithelial lines, generate CD11b+ cells capable of inducing endothelial cell sprouting in vitro and angiogenesis in vivo. An anti–Flt-1 mAb or soluble Flt-1 abolished the generation of proangiogenic activity during differentiation from progenitor cells. Moreover, inhibition of metalloproteinase activity, but not VEGF, during the endothelial sprouting assay blocked sprouting induced by these proangiogenic CD11b+ myelomonocytes. In a mouse model of breast cancer, circulating CD11b+ cells were proangiogenic in the sprouting assays. Silencing of PlGF in tumor cells prevented the generation of proangiogenic activity in circulating CD11b+ cells, inhibited tumor blood flow, and slowed tumor growth. Peripheral blood of breast cancer patients at diagnosis, but not of healthy individuals, contained elevated levels of PlGF and circulating proangiogenic CD11b+ myelomonocytes. Taken together, our results show that cancer cells can program proangiogenic activity in CD11b+ myelomonocytes during differentiation of their progenitor cells in a PlGF-dependent manner. These findings impact breast cancer biology, detection, and treatment. Cancer Res; 71(11); 3781–91. ©2011 AACR.
Collapse
Affiliation(s)
- Julien Laurent
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Eveline Faes-van't Hull
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Cedric Touvrey
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - François Kuonen
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Qiang Lan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Girieca Lorusso
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Marie-Agnès Doucey
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Laura Ciarloni
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Natsuko Imaizumi
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Gian Carlo Alghisi
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Ernesta Fagiani
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Khalil Zaman
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Roger Stupp
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Masabumi Shibuya
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Jean-François Delaloye
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Gerhard Christofori
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Curzio Ruegg
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| |
Collapse
|